- Silo Pharma Inc SILO has announced proof-of-concept data supporting the therapeutic potential of SPC-14 for the treatment of Alzheimer’s disease (AD).
- The research was conducted under a sponsored research agreement with Columbia University in New York.
- Silo Pharma’s Commercial Evaluation License Agreement (CELA) with Columbia University provides an option to license two investigational compounds — SPC-14, targeting Alzheimer’s disease, and SPC-15, targeting stress-induced mood disorders.
- SPC-14 combines an FDA-approved therapeutic with ketamine. It is in development for dementia associated with Alzheimer’s disease.
- Initial data from his SPC-14 research studies show that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no adverse effects on subjects’ weight.
- “The outcome of these studies is a first step in the development of SPC-14 as a potential therapeutic for the treatment of Alzheimer’s disease,” said Eric Weisblum, Chief Executive Officer of Silo Pharma… We believe SPC-14 should be amenable to development under FDA pathway 505(b)(2). This will allow Silo Pharma to reach efficacy clinical trials faster and save costs.”
- Earlier this week, Columbia University granted Silo an extension to her Option to license specific assets currently under development, including Alzheimer’s disease and stress-induced anxiety.
- Price promotion: SILO shares closed at $4.78 on Wednesday.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
